Posted by Michael Wonder on 23 Nov 2023
Evive Biotech and Acrotech Biopharma announce FDA approval of Ryzneuta (efbemalenograstim alfa injection) for chemotherapy-induced neutropenia
22 November 2023 - Ryzneuta is the first non-pegylated granulocyte colony-stimulating factor approved by both the US FDA and China NMPA for treatment for chemotherapy-induced neutropenia.
Evive Biotech and Acrotech Biopharma today announced that on 16 November 2023, the US FDA approved Ryzneuta (efbemalenograstim alfa) indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
